Literature DB >> 21119622

Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells.

Amal Kambal1, Gaela Mitchell, Whitney Cary, William Gruenloh, Yunjoon Jung, Stefanos Kalomoiris, Catherine Nacey, Jeannine McGee, Matt Lindsey, Brian Fury, Gerhard Bauer, Jan A Nolta, Joseph S Anderson.   

Abstract

Induced pluripotent stem cells (iPSCs) have radically advanced the field of regenerative medicine by making possible the production of patient-specific pluripotent stem cells from adult individuals. By developing iPSCs to treat HIV, there is the potential for generating a continuous supply of therapeutic cells for transplantation into HIV-infected patients. In this study, we have used human hematopoietic stem cells (HSCs) to generate anti-HIV gene expressing iPSCs for HIV gene therapy. HSCs were dedifferentiated into continuously growing iPSC lines with four reprogramming factors and a combination anti-HIV lentiviral vector containing a CCR5 short hairpin RNA (shRNA) and a human/rhesus chimeric TRIM5α gene. Upon directed differentiation of the anti-HIV iPSCs toward the hematopoietic lineage, a robust quantity of colony-forming CD133(+) HSCs were obtained. These cells were further differentiated into functional end-stage macrophages which displayed a normal phenotypic profile. Upon viral challenge, the anti-HIV iPSC-derived macrophages exhibited strong protection from HIV-1 infection. Here, we demonstrate the ability of iPSCs to develop into HIV-1 resistant immune cells and highlight the potential use of iPSCs for HIV gene and cellular therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119622      PMCID: PMC3048185          DOI: 10.1038/mt.2010.269

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

Review 1.  Resistance to novel drug classes.

Authors:  Anne-Genevieve Marcelin; Francesca Ceccherini-Silberstein; Carlo-Federico Perno; Vincent Calvez
Journal:  Curr Opin HIV AIDS       Date:  2009-11       Impact factor: 4.283

2.  Definitive proof for direct reprogramming of hematopoietic cells to pluripotency.

Authors:  Motohito Okabe; Makoto Otsu; Dong Hyuck Ahn; Toshihiro Kobayashi; Yohei Morita; Yukiko Wakiyama; Masafumi Onodera; Koji Eto; Hideo Ema; Hiromitsu Nakauchi
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

3.  Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice.

Authors:  Qizhou Lian; Yuelin Zhang; Jinqiu Zhang; Hua Kun Zhang; Xingang Wu; Yang Zhang; Francis Fu-Yuen Lam; Sarang Kang; Jian Chuan Xia; Wing-Hong Lai; Ka-Wing Au; Yen Yen Chow; Chung-Wah Siu; Chuen-Neng Lee; Hung-Fat Tse
Journal:  Circulation       Date:  2010-02-22       Impact factor: 29.690

4.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

5.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:  Ronald T Mitsuyasu; Thomas C Merigan; Andrew Carr; Jerome A Zack; Mark A Winters; Cassy Workman; Mark Bloch; Jacob Lalezari; Stephen Becker; Lorna Thornton; Bisher Akil; Homayoon Khanlou; Robert Finlayson; Robert McFarlane; Don E Smith; Roger Garsia; David Ma; Matthew Law; John M Murray; Christof von Kalle; Julie A Ely; Sharon M Patino; Alison E Knop; Philip Wong; Alison V Todd; Margaret Haughton; Caroline Fuery; Janet L Macpherson; Geoff P Symonds; Louise A Evans; Susan M Pond; David A Cooper
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

6.  Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.

Authors:  Joseph S Anderson; John Javien; Jan A Nolta; Gerhard Bauer
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

7.  Generation of functional human hepatic endoderm from human induced pluripotent stem cells.

Authors:  Gareth J Sullivan; David C Hay; In-Hyun Park; Judy Fletcher; Zara Hannoun; Catherine M Payne; Donna Dalgetty; James R Black; James A Ross; Kay Samuel; Gang Wang; George Q Daley; Je-Hyuk Lee; George M Church; Stuart J Forbes; John P Iredale; Ian Wilmut
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 8.  Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.

Authors:  Dan S Kaufman
Journal:  Blood       Date:  2009-08-03       Impact factor: 22.113

9.  Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells.

Authors:  Shogo Nagata; Masashi Toyoda; Shinpei Yamaguchi; Kunio Hirano; Hatsune Makino; Koichiro Nishino; Yoshitaka Miyagawa; Hajime Okita; Nobutaka Kiyokawa; Masato Nakagawa; Shinya Yamanaka; Hidenori Akutsu; Akihiro Umezawa; Takashi Tada
Journal:  Genes Cells       Date:  2009-11-13       Impact factor: 1.891

10.  Telomere dynamics in human cells reprogrammed to pluripotency.

Authors:  Steven T Suhr; Eun Ah Chang; Ramon M Rodriguez; Kai Wang; Pablo J Ross; Zeki Beyhan; Shashanka Murthy; Jose B Cibelli
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more
  34 in total

1.  Induction of human embryonic and induced pluripotent stem cells into urothelium.

Authors:  Stephanie L Osborn; Ravikumar Thangappan; Ayala Luria; Justin H Lee; Jan Nolta; Eric A Kurzrock
Journal:  Stem Cells Transl Med       Date:  2014-03-21       Impact factor: 6.940

Review 2.  HIV/AIDS: modified stem cells in the spotlight.

Authors:  Enrique Armijo; Claudio Soto; Brian R Davis
Journal:  Cell Mol Life Sci       Date:  2014-02-08       Impact factor: 9.261

Review 3.  Induced pluripotent stem cells as a disease modeling and drug screening platform.

Authors:  Antje D Ebert; Ping Liang; Joseph C Wu
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105

4.  Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.

Authors:  Jon E Walker; Rachel X Chen; Jeannine McGee; Catherine Nacey; Richard B Pollard; Mehrdad Abedi; Gerhard Bauer; Jan A Nolta; Joseph S Anderson
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

5.  Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection.

Authors:  Lin Ye; Jiaming Wang; Ashley I Beyer; Fernando Teque; Thomas J Cradick; Zhongxia Qi; Judy C Chang; Gang Bao; Marcus O Muench; Jingwei Yu; Jay A Levy; Yuet Wai Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

6.  Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene.

Authors:  Ulrike Jung; Kevin Urak; Maxime Veillette; Marie-Édith Nepveu-Traversy; Quang Toan Pham; Sophie Hamel; John J Rossi; Lionel Berthoux
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

Review 7.  Nanotechnology approaches to eradicating HIV reservoirs.

Authors:  Shijie Cao; Kim A Woodrow
Journal:  Eur J Pharm Biopharm       Date:  2018-06-04       Impact factor: 5.571

Review 8.  Development of autologous blood cell therapies.

Authors:  Ah Ram Kim; Vijay G Sankaran
Journal:  Exp Hematol       Date:  2016-06-21       Impact factor: 3.084

9.  A novel aminoacid determinant of HIV-1 restriction in the TRIM5α variable 1 region isolated in a random mutagenic screen.

Authors:  Quang Toan Pham; Maxime Veillette; Alberto Brandariz-Nuñez; Paulina Pawlica; Caroline Thibert-Lefebvre; Nadia Chandonnet; Felipe Diaz-Griffero; Lionel Berthoux
Journal:  Virus Res       Date:  2013-01-25       Impact factor: 3.303

Review 10.  Creating genetic resistance to HIV.

Authors:  John C Burnett; John A Zaia; John J Rossi
Journal:  Curr Opin Immunol       Date:  2012-09-15       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.